Inactive Instrument

CMIC HLDG

Equities

2309

JP3359000001

CMIC : Overview of Financial Results For the 2nd Quarter FY2022

April 28, 2022 at 12:35 pm IST

CMIC HOLDINGS Co., Ltd.

April 28, 2022

ChinaKorea

HongKong

VietnamTaiwanThailandPhilippines

Malaysia

Singapore

Global : 14

（Plants : 2, Lab : 1）

Offices

PlantsLab

USA

Australia

Change in reportable segment

From FY22, there will be two reportable segments: Pharmaceutical Solutions, which expands PVC models, and Healthcare Solutions, which contributes to the health of individuals through medical institutions and local governments, etc.

Focus Activities of Mid-term Management Plan (FY2022-25)

Evolution of healthcare business

Comprehensive support for disease prevention, treatment R&D, and marketing

Contribution to sustainable society through services with high social benefits

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original Link
Original Document
Permalink

Disclaimer

CMIC Holdings Co. Ltd. published this content on 28 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2022 07:04:07 UTC.

Latest news about CMIC HLDG

CMIC Holdings Delisted from Tokyo Stock Exchange	28/03	MT
CMIC to Delist After Shareholder Go-Ahead for Proposed Share Consolidation	05/03	MT
CMIC Holdings to Hold Shareholders Meeting to Vote on Share Consolidation and Amendment on March 4	01/02	MT
Japan's small cohort of listed firms led by women	31/01	RE
CMIC HOLDINGS Co., Ltd.(TSE:2309) dropped from S&P Global BMI Index	17/01	CI
CMIC Holdings Finalizes Tender Offer; Delisting Underway as Sole Shareholders Change	05/01	MT
SORA Corporation completed the acquisition of 55.42% CMIC HOLDINGS Co., Ltd..	04/01	CI
CMIC to Distribute 45 yen per Share Surplus Dividend, Plans to Buy Back Shares	16/11	MT
CMIC HOLDINGS Co., Ltd. Announces Dividend for the Year Ended September 30, 2023, Payable on December 1,2023	15/11	CI
Cmic Holdings Co., Ltd. Announces Retirement of Takeshi Hamaura as Corporate Director	07/11	CI
SORA Corporation made an offer to acquire 67.23% stake in CMIC HOLDINGS Co., Ltd. for ¥33.7 billion.	07/11	CI
CMIC HOLDINGS Co., Ltd. completed the acquisition of Hamamatsu Pharma Research Inc. from Hiroyuki Takamatsu.	31/23/31	CI
CMIC Holdings Expands PHVC Business Model with Acquisition of Hamamatsu Pharma Research	27/23/27	MT
CMIC HOLDINGS Co., Ltd. signed a contract to acquire Hamamatsu Pharma Research Inc. from Hiroyuki Takamatsu.	26/23/26	CI
CMIC Holdings Repurchases 114,000 Shares; Completes Share Buyback Mandate Approved in November 2022	15/23/15	MT
Tranche Update on CMIC HOLDINGS Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.	14/23/14	CI
CMIC HOLDINGS Co., Ltd.'s Equity Buyback announced on November 8, 2022, has closed with 652,300 shares, representing 3.77% for ¥1,199.89 million.	10/23/10	CI
Transcript : CMIC HOLDINGS Co., Ltd., Q3 2023 Earnings Call, Aug 01, 2023	01/23/01
CMIC Repurchases Shares in June	04/23/04	MT
Tranche Update on CMIC HOLDINGS Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.	03/23/03	CI
Transcript : CMIC HOLDINGS Co., Ltd., Q2 2023 Earnings Call, May 16, 2023	16/23/16
CMIC HOLDINGS Co., Ltd. Reports Earnings Results for the Half Year Ended March 31, 2023	28/23/28	CI
CMIC HOLDINGS Co., Ltd. Announces Dividend for Second Quarter Ended March 31, 2023; Provides Year-End Dividend Guidance for the Fiscal Year Ending September 30, 2023	28/23/28	CI
CMIC HOLDINGS Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended September 30, 2023	28/23/28	CI
CMIC Repurchases Shares for 98 Million Yen in March	04/23/04	MT

Chart CMIC HLDG

Duration

Period

More charts

Company Profile

CMIC HOLDINGS Co., Ltd. mainly provides pharmaceutical development support services. The Contract Research Organization (CRO) segment offers monitoring, data management, pharmaceutical consulting and nonclinical services. The Contract Manufacturing Organization (CMO) segment is engaged in the entrusted manufacture of drugs for pharmaceutical companies. The Contract Sales Organization (CSO) segment is engaged in the operation and marketing support for medicinal products. The Health Care segment conducts site support institute (SMO) business, and provides health care information services. The Intellectual Property Development (IPD) segment develops and sells diagnostic products and orphan drugs.

Sector

More about the company